Stock

Olympus says CEO steps down after allegations of illegal drug purchase

TOKYO (Reuters) -Japanese medical equipment maker Olympus Corp said on Monday that Chief Executive Stefan Kaufmann has stepped down after allegations he purchased illegal drugs, sending its shares sharply lower.

“Upon receiving an allegation that Mr. Stefan Kaufmann had purchased illegal drugs … Olympus, in consultation with outside legal counsel, immediately investigated the facts,” the company said in a statement.

“Based on the results of the investigation, the Board of Directors unanimously determined that Mr. Stefan Kaufmann likely engaged in behaviours that were inconsistent with our global code of conduct, our core values, and our corporate culture.”

Following the board decision, Kaufmann was asked to offer his resignation and he complied, the statement said.

Reuters was unable to reach Kaufmann for comment.

Yasuo Takeuchi, a director who has formerly helmed the company, will carry out the duties of the CEO for the time being, Olympus said.

Olympus shares tumbled 5.7% in morning trade, underperforming the Nikkei average which was up 1.6%.

This post appeared first on investing.com

You May Also Like

Editor's Pick

Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

Latest News

A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 balanceandcharge.com

Exit mobile version